Susceptibilities of human ACE2 genetic variants in coronavirus infection
Wenlin Ren,Yunkai Zhu,Jun Lan,Hedi Chen,Yuyan Wang,Hongyang Shi,Fei Feng,Da-Yuan Chen,Brianna Close,Xiaomin Zhao,Jianping Wu,Boxue Tian,Zhenghong Yuan,Dongming Zhou,Mohsan Saeed,Xinquan Wang,Rong Zhang,Qiang Ding,Wenlin RenYunkai ZhuJun LanHedi ChenYuyan WangHongyang ShiFei FengDa-Yuan ChenBrianna CloseXiaomin ZhaoJianping WuBoxue TianZhenghong YuanDongming ZhouMohsan SaeedXinquan WangRong ZhangQiang Ding1Center for Infectious Disease Research,School of Medicine,Tsinghua University,Beijing 100084,China2Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS),School of Basic Medical Sciences,Shanghai Medical College,Biosafety Level 3 Laboratory,Fudan University,Shanghai 200032,China3School of Life Sciences,Tsinghua University,Beijing 100084,China4School of Pharmaceutical Sciences,Tsinghua University,Beijing 100084,China5CAS Key Laboratory of Molecular Virology and Immunology,Institut Pasteur of Shanghai,Chinese Academy of Sciences,Shanghai,China6Department of Biochemistry,Boston University School of Medicine,Boston,MA,United States of America7National Emerging Infectious Diseases Laboratories,Boston University,Boston,MA,United States of America8Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,18 Shilongshan Road,Hangzhou 310024,Zhejiang Province,China9Department of Pathogen Biology,School of Basic Medical Sciences,Tianjin Medical University,Tianjin,China
DOI: https://doi.org/10.1128/jvi.01492-21
IF: 6.549
2021-10-21
Journal of Virology
Abstract:The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in more than 235 million cases worldwide and 4.8 million deaths (October 2021), with varying incidences and mortalities among regions/ethnicities. The coronaviruses SARS-CoV, SARS-CoV-2 and HCoV-NL63 utilize the angiotensin-converting enzyme 2 (ACE2) as the receptor to enter cells. We hypothesized that the genetic variability in ACE2 may contribute to the variable clinical outcomes of COVID-19. To test this hypothesis, we first conducted an in silico investigation of single-nucleotide polymorphisms (SNPs) in the coding region of ACE2. We then applied an integrated approach of genetics, biochemistry and virology to explore the capacity of select ACE2 variants to bind coronavirus spike proteins and mediate viral entry. We identified the ACE2 D355N variant that restricts the spike protein-ACE2 interaction and consequently limits infection both in vitro and in vivo . In conclusion, ACE2 polymorphisms could modulate susceptibility to SARS-CoV-2, which may lead to variable disease severity. IMPORTANCE There is considerable variation in disease severity among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19). Human genetic variation can affect disease outcome, and the coronaviruses SARS-CoV, SARS-CoV-2 and HCoV-NL63 utilize human angiotensin-converting enzyme 2 (ACE2) as the receptor to enter cells. We found that several missense ACE2 SNVs that showed significantly altered binding with the spike proteins of SARS-CoV, SARS-CoV-2 and NL63-HCoV. We identified an ACE2 SNP D355N that restricts the spike protein-ACE2 interaction and consequently have the potential to protect individuals against SARS-CoV-2 infection. Our study highlights ACE2 polymorphisms could impact human susceptibility to SARS-CoV-2, which may contribute to ethnic and geographical differences in SARS-CoV-2 spread and pathogenicity.
virology